Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopinath Ranganna

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 9, 2020
The Path Towards a Tailored Clinical Biosimilar DevelopmentMartin Schiestl, Gopinath Ranganna, Keith Watson, et al.
Diabetes, Obesity & Metabolism|August 11, 2021
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp studyUlrike Hövelmann, Yaron Raiter, Anoop Chullikana, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyThomas C Blevins, Yaron Raiter, Bin Sun, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancerMark A Socinski, Cornelius F Waller, Tazeen Idris, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 4, 2023
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin<sup>®</sup>) in Patients with Non-squamous Non-small Cell Lung CancerJoel S Owen, Russell J Rackley, Matthew A Hummel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 9, 2020
The Path Towards a Tailored Clinical Biosimilar DevelopmentMartin Schiestl, Gopinath Ranganna, Keith Watson, et al.
Diabetes, Obesity & Metabolism|August 11, 2021
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp studyUlrike Hövelmann, Yaron Raiter, Anoop Chullikana, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2022
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog<sup>®</sup>) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label StudyThomas C Blevins, Yaron Raiter, Bin Sun, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancerMark A Socinski, Cornelius F Waller, Tazeen Idris, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 4, 2023
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin<sup>®</sup>) in Patients with Non-squamous Non-small Cell Lung CancerJoel S Owen, Russell J Rackley, Matthew A Hummel, et al.
Pageof 1